GL Pharm Tech Corp

GL Pharm Tech Corp has a market capitalization of KRW 77.55 billion and a price-to-book ratio of 3.89, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 1.01 and negative free cash flow of KRW -2.19 billion, suggesting limited short-term liquidity flexibility. The company's debt-to-equity ratio of 0.94 reflects a moderate leverage position, with long-term debt of KRW 18.73 billion against total equity of KRW 19.92 billion. Profitability metrics show a return on equity (ROE) of 0.06% and a return on assets (ROA) of 0.03%, both significantly below the industry median for biotechnology and medical research firms. The company's operating income of KRW 268.48 million and net income of KRW 12.49 million indicate minimal profitability, with a gross margin of 40.63% (KRW 14.33 billion gross profit on KRW 35.27 billion revenue). These figures suggest the company is not yet generating strong returns relative to its asset base or equity. The company's revenue is concentrated in a single disclosed segment, healthcare diagnostics, with no geographic breakdown provided in the latest financials. This lack of diversification increases exposure to market-specific risks, particularly in the Korean healthcare diagnostics market. No competitor revenue shares are available in the input data, but the company's revenue of KRW 35.27 billion is relatively modest compared to industry leaders. Outlook data is not provided in the input, but the company's operating cash flow of KRW -1.12 billion and free cash flow of KRW -2.19 billion suggest a need for external financing or cost control to sustain operations. The capital expenditure of KRW -3.2 billion indicates ongoing investment in infrastructure or R&D, which is typical for early-stage biotechnology firms. However, without a clear revenue growth trajectory or margin expansion plan, the company's long-term viability remains uncertain. Risk factors include a negative net cash position after subtracting total debt, which is flagged as a key liquidity risk. The company's dilution risk is assessed as low, with no near-term pressure expected, and no recent equity issuance or ATM/shelf disclosures reported in the input data. No regulatory or geopolitical risks are explicitly cited in the input, but the healthcare diagnostics industry is subject to regulatory changes and patent risks. Recent events include the company's transition from a special purpose acquisition company to a biotechnology and medical research firm, as disclosed in its filings. No recent earnings call transcripts or material events are provided in the input data.